Clinical Trial Update: A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-7962-006/ZENITH evaluating sotatercept in pulmonary arterial hypertension patients at high mortality risk has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Sotatercept (sotatercept)

Snippet

Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2025-08-22